Sage confirms suspension of 2 depression trials after PhIII flop; Esperion follows up maiden approval with combo OK
→ In the wake of a flop in the crucial Phase III MOUNTAIN study, Sage Therapeutics confirmed in its quarterly update that it’s …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
